908 Devices (MASS) to Release Quarterly Earnings on Monday

908 Devices (NASDAQ:MASS) is expected to announce its Q3 2025 results before the market opens on Monday, November 10th. Analysts expect 908 Devices to post earnings of ($0.12) per share and revenue of $13.5780 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 10, 2025 at 8:30 AM ET.

908 Devices (NASDAQ:MASS) last released its quarterly earnings data on Tuesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The firm had revenue of $4.70 million during the quarter, compared to analyst estimates of $12.17 million. 908 Devices had a negative return on equity of 24.30% and a negative net margin of 30.54%. On average, analysts expect 908 Devices to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

908 Devices Stock Down 5.4%

908 Devices stock opened at $7.38 on Friday. 908 Devices has a 52-week low of $1.81 and a 52-week high of $9.34. The firm has a market capitalization of $264.65 million, a price-to-earnings ratio of -13.67 and a beta of 0.45. The firm has a 50-day moving average price of $7.59 and a two-hundred day moving average price of $6.75.

Insider Activity at 908 Devices

In other news, CFO Joseph H. Iv Griffith sold 4,292 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $9.05, for a total value of $38,842.60. Following the completion of the sale, the chief financial officer owned 92,930 shares in the company, valued at $841,016.50. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Over the last 90 days, insiders sold 10,000 shares of company stock valued at $80,593. 23.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On 908 Devices

Several large investors have recently made changes to their positions in MASS. Manatuck Hill Partners LLC bought a new stake in shares of 908 Devices in the 2nd quarter worth approximately $570,000. Bank of America Corp DE increased its holdings in shares of 908 Devices by 221.7% in the second quarter. Bank of America Corp DE now owns 363,217 shares of the company’s stock valued at $2,590,000 after buying an additional 250,311 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of 908 Devices during the 2nd quarter valued at $341,000. Raymond James Financial Inc. bought a new stake in shares of 908 Devices during the 2nd quarter worth $48,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of 908 Devices in the 2nd quarter worth $77,000. Institutional investors own 88.06% of the company’s stock.

Analyst Upgrades and Downgrades

MASS has been the subject of several analyst reports. Leerink Partnrs upgraded 908 Devices from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 5th. Wall Street Zen raised 908 Devices from a “sell” rating to a “hold” rating in a research note on Monday, September 15th. Leerink Partners raised 908 Devices from a “market perform” rating to an “outperform” rating and set a $12.00 price target for the company in a research note on Tuesday, August 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 908 Devices in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.00.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.